Clinicopathological Characteristics and Recurrence-Free Survival of Rare Variants of Papillary Thyroid Carcinomas in Korea: A Retrospective Study

Mijin Kim1,*, Sun Wook Cho2,*, Young Joo Park3, Hwa Young Ahn3, Hee Sung Kim4, Yong Joon Suh5, Dughyun Choi6, Bu Kyung Kim7, Go Eun Yang8, Il-Seok Park2, Ka Hee Yi10, Chan Kwon Jung11, Bo Hyun Kim1

1Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Busan; 2Department of Internal Medicine, Seoul National University Hospital; 3Division of Endocrinology, Department of Internal Medicine, 4Department of Pathology, Chung-Ang University College of Medicine, Seoul; 5Department of Breast and Endocrine Surgery, Hallym University Sacred Heart Hospital, Anyang; 6Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon; 7Department of Internal Medicine, Kosin University College of Medicine, Busan; 8Department of Radiology, School of Medicine, Kangwon National University Hospital, Chuncheon; 9Department of Otorhinolaryngology-Head and Neck Surgery, Hallym University Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong; 10Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center; 11Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, Seoul, Korea

Background: We aimed to evaluate the clinicopathological features and biological behaviors of Korean thyroid cancer patients with rare variants of papillary thyroid carcinoma (PTC) to address the ambiguity regarding the prognostic consequences of these variants.

Methods: We retrospectively reviewed the medical records of 5,496 patients who underwent thyroid surgery for PTC, between January and December 2012, in nine tertiary hospitals. Rare PTC variants included tall cell (TCV), columnar cell (CCV), diffuse sclerosing (DSV), cribriform-morular (CMV), solid (SV), hobnail, and Warthin-like variants. Recurrence-free survival (RFS) was defined as the time from the date of thyroidectomy until recurrence.

Results: Rare variants accounted for 1.1% (n=63) of the PTC patients; with 0.9% TCV, 0.02% CCV, 0.1% DSV, 0.1% CMV, and 0.1% SV. The mean age of patients and primary tumor size were 42.1±13.1 years and 1.3±0.9 cm, respectively. Extrathyroidal extension and cervical lymph node metastasis were observed in 38 (60.3%) and 37 (58.7%) patients, respectively. Ultrasonographic findings revealed typical malignant features in most cases. During a median follow-up of 7 years, 6.3% of patients experienced a locoregional recurrence. The 5-year RFS rates were 71.4% in patients with DSV or SV, 95.9% for TCV, or CCV, and 100% for other variants. DSV emerged an independent risk factor associated with shorter RFS.

Copyright © 2021 Korean Endocrine Society
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION

Papillary thyroid carcinoma (PTC) is the most common thyroid malignancy with an indolent clinical course [1,2]. Classical PTC accounts for 55% to 65% of the cases; while, more than 10 different variants have been identified [3]. Among these, follicular variant is a common subtype, accounting for about 15% to 30% of all PTCs, and its incidence has increased in recent times [4-7]. The other, relatively rare subtypes include tall cell (TCV), columnar cell (CCV), diffuse sclerosing (DSV), cribriform-morular (CMV), solid (SV), hobnail (HV), and Warthin-like variants [8,9]. The prevalence of these variants differs between regions, countries, and patient populations [9]. The incidence of TCV ranges from 4% to 16%, and it does not constitute a common pathological entity when a strict pathologic definition is applied [5,7,10,11]. The other variants are rarer, accounting for 1% to 3% of PTC [10-21]. Owing to their rarity, most studies on PTC variants largely consist of case reports with few large-sample analyses or multicenter cross-sectional studies [9].

Rare variants have distinct clinical, pathological, and prognostic characteristics [8]. Certain variants have more aggressive or, conversely, more favorable tumor behaviors than classic PTCs; therefore, they contribute to risk stratification [8]. According to the American Thyroid Association (ATA) initial risk stratification, PTCs are classified into three major groups based on their biological behaviors: (1) aggressive variants with unfavorable outcomes, including TCV, CCV, and HV; (2) variants with less favorable outcomes but controversy exists regarding their mortality rate, including SV and DSV; and (3) other variants [8]. However, the prognostic implications of these PTC variants remain controversial [8]. For example, a Korean single-centered study, conducted on 144 patients with aggressive variants of PTC, revealed that patients with TCV did not exhibit worse clinical outcomes when compared to those with classic PTC, diagnosed with similar clinicopathological factors [10]. CCV was associated with poorer clinical outcomes after propensity score matching [10]. Additionally, some studies suggest that SV and DSV could be classified as a high-risk pathological entity due to their propensity for recurrence [14,15,22-26]. A large, multicentered study in France revealed that patients with DSV were at a nine times higher risk of recurrence than patients with other variants of PTC, despite aggressive surgical interventions that required more frequent follow-ups [15]. Nevertheless, these variants usually occur in young patients and are highly responsive to treatment, with a lower mortality rate. Therefore, there is a lack of clarity regarding the pathological subtypes that require more aggressive treatment and careful surveillance.

In this multicenterized study conducted in Korea, we aimed to evaluate the clinicopathologic characteristics and biological behaviors of patients with rare variants of PTC using a large, multicenter cohort of thyroid cancer patients. Additionally, we elucidated the prognostic factors associated with recurrence-free survival (RFS) in PTC patients with rare variants.

METHODS

Patients

We retrospectively reviewed the medical records of 5,496 consecutive patients who underwent thyroid surgery for PTC, between January 2012 and December 2012, at nine tertiary hospitals in the Republic of Korea. All patients were above 18 years of age. Of these, we identified 63 patients with uncommon pathological variants; including cases other than classical or follicular variant PTC. The largest tumor was considered as the primary lesion in cases of multiple tumor foci with different sizes. From the electronic medical records, we obtained their clinical and pathological data, including age, sex, primary tumor size, ultrasonography (US) findings, pathological report, extent of surgery, presence of distant metastases, use of radioactive iodine (RAI) ablation, RAI dose, recurrence, date of recurrence, survival status, date of last follow-up, and cause of death. Recurrence was defined as the appearance of pathologically confirmed malignant tissue and/or metastatic lesions. RFS was defined as the time from the date of thyroideotomy until recurrence.

The relevant Institutional Review Boards approved our study protocol (Pusan National University Hospital, 1906-002-079; Seoul National University Hospital, 1905-155-1035; Chung-Ang University Hospital, 1906-006-16266; Hallym University Dongtan Sacred Heart Hospital, 2019-06-011; Soonchunhyang University Bucheon Hospital, 2019-05-014; Hallym University Bucheon Hospital, 2019-05-014; Hallym University Bucheon Hospital, 2019-05-014; Hallym University Bucheon Hospital, 2019-05-014).

Conclusion: In this multicenter Korean cohort, rare variants accounted for 1.1% of all PTC cases, with TCV being the most frequent subtype. DSV emerged as a significant prognostic factor for RFS.

Keywords: Thyroid neoplasms; Carcinoma, papillary; Prognosis; Recurrence; Prevalence
Sacred Heart Hospital, 2020-09-015; Kosin University Gospel Hospital, 2019-05-015; Kangwon National University Hospital, KNUH-2019-06-002; Seoul St. Mary’s Hospital, KC16SI-SI0104). They waived the requirement of informed consent from the participants due to the retrospective design of the study.

Classification of histologic variants
Practicing pathologists made pathologic diagnosis and classified the histologic variants of PTCs in their routine clinical practice, using the 2004 World Health Organization classification of tumors of endocrine organs [27]. According to this classification, PTC was diagnosed as TCV when tall cells with a height-to-width ratio of ≥3 comprised more than 50% of all tumor cells [27].

Variant groups
Rare variants of PTC included TCV, CCV, DSV, CMV, SV, HV, and Warthin-like variants. These variants were categorized into the following three groups based on the ATA guidelines [8]: (1) aggressive variants, including TCV, CCV, and HV; (2) those (SV and DSV) with less favorable outcomes but controversy exists regarding mortality rate; and (3) other uncommon variants, including CMV and Warthin-like variant.

Ultrasoundography analysis
Experienced radiologists from each institution investigated the US features of the tumors, using a picture archiving and communication system. These features included the composition, echogenicity, calcification, margin, and shape of the tumors. For every nodule, we used the consensus ratings for each US feature to classify the risk of malignancy, according to the 2015 guidelines of the ATA classification [8]. The information on preoperative US images of three patients was unavailable.

Statistical analysis
Statistical analyses were performed using the R program version 3.6.2 (The R Project for Statistical Computing, Vienna, Austria). Survival curves and forest plot were plotted using GraphPad Prism version 5.0 (GraphPad Software Inc., San Diego, CA, USA) and MedCalc Statistical Software version 19.5.3 (MedCalc Software Ltd., Ostend, Belgium), respectively. Continuous variables are presented as mean±standard deviation, and categorical variables are presented as numbers (%). RFS curves were plotted using the Kaplan-Meier method, and the log-rank test was used to determine the significance of difference. The relative risks for RFS were evaluated using the Cox proportional hazards model and presented as hazard ratios (HRs), 95% confidence intervals (CIs), and P values. The Cox proportional hazards model was also used to analyze the prognostic factors associated with RFS. All P values were two-sided, and P<0.05 was considered statistically significant.

RESULTS

Clinicopathological characteristics
Rare variants of PTC were found in 63 (1.1%) of 5,496 patients

Institution | Sample size | Proportion | 95% CI | Weight (%)
--- | --- | --- | --- | ---
A | 642 | 0.0% | 0.0 to 0.7 | 13.3
B | 285 | 0.0% | 0.0 to 1.3 | 12.0
C | 25 | 0.0% | 0.0 to 13.7 | 4.3
D | 1,061 | 0.2% | 0.0 to 0.7 | 13.8
E | 350 | 0.6% | 0.1 to 2.0 | 12.4
F | 1,518 | 0.7% | 0.4 to 1.3 | 14.0
G | 648 | 1.1% | 0.4 to 2.2 | 13.3
H | 949 | 4.2% | 3.0 to 5.7 | 13.7
I | 18 | 5.6% | 0.1 to 27.3 | 3.4
Total (fixed effects) | 5,496 | 0.9% | 0.6 to 1.1 | 100.0
Total (random effects) | 5,496 | 0.8% | 0.2 to 1.9 | 100.0

Fig. 1. Forest plot for the overall pooled prevalence of rare variants of papillary thyroid carcinoma. The size of the box represents the weight given to each institution. The whiskers indicate the 95% confidence interval (CI).
with PTC and included 51 (0.9%) TCV, one (0.02%) CCV, four (0.1%) DSV, three (0.1%) CMV, and four (0.1%) SV cases. HV and Warthin-like variants were not identified in this cohort. The incidence of rare variants varied from 0% to 5.6% of all PTCs from nine institutions. The overall pooled prevalence of rare variants was 0.8% (95% CI, 0.2 to 1.9) as shown in Fig. 1.

Table 1 lists the baseline characteristics of the 63 PTC patients with rare variants. The mean age of patients was 42.1 ± 13.1 years, and 15.9% \((n=10)\) of them were males. The mean primary tumor size was 1.3 ± 0.9 cm, and 33 (52.4%) patients had tumors larger than 1 cm. Lymphovascular invasion, microscopic extrathyroidal extension (ETE), and gross ETE were observed in 22 (34.9%), 30 (47.6%) and eight (12.7%) patients, respectively. Cervical lymph node (LN) metastases were detected in 37 (58.7%) patients, including 29 (46.0%) patients with N1a stage and eight (12.7%) patients with N1b stage metastases. None of the patients were diagnosed with distant metastases. Most patients underwent total thyroidectomy (93.7%) and 10 patients initially underwent lateral neck dissection. All patients who underwent hemithyroidectomy had a tumor size < 1 cm, and no patients underwent completion thyroidectomy. Fifty-three patients (84.1%) received RAI therapy with a mean dose of 104.4 ± 74.8 mCi. Based on the ATA classification, we classified 45 (75%) and 15 (25%) patients into high and intermediate suspicion categories, respectively (Table 2). The prominent US features of these tumors included hypoechogenicity (83.3%), microcalcification (43.3%), irregular or microlobulated margins (76.7%), and taller-than-wide shape (36.7%).

### Recurrence-free survival

During the median follow-up of 7 years, locoregional recurrences occurred in four patients: two patients each with TCV and DSV. These patients underwent total thyroidectomy with neck LN dissection (central only for three patients, and central plus lateral for one patient) initially, and three of them had an N1a tumor. All recurrences were confirmed pathologically; one was initially detected using a post-RAI scan, and the others using follow-up US images. The 5-year RFS rate for rare variants in PTC patients was 93.3%, and the RFS curves significantly differed according to variant subtypes \((P=0.004)\) (Fig. 2A).

### Table 1. Baseline Characteristics of Patients with Rare Variants of Papillary Thyroid Carcinoma

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>63</td>
</tr>
<tr>
<td>Age, yr</td>
<td>42.1 ± 13.1</td>
</tr>
<tr>
<td>Male patients</td>
<td>10 (15.9)</td>
</tr>
<tr>
<td>Pathology, variant</td>
<td></td>
</tr>
<tr>
<td>Tall cell</td>
<td>51 (81.0)</td>
</tr>
<tr>
<td>Columnar cell</td>
<td>1 (1.6)</td>
</tr>
<tr>
<td>Diffuse sclerosing</td>
<td>4 (6.3)</td>
</tr>
<tr>
<td>Cribriform-morular</td>
<td>3 (4.8)</td>
</tr>
<tr>
<td>Solid</td>
<td>4 (6.3)</td>
</tr>
<tr>
<td>Hobnail</td>
<td>0</td>
</tr>
<tr>
<td>Warthin-like</td>
<td>0</td>
</tr>
<tr>
<td>Primary tumor size, cm</td>
<td>1.3 ± 0.9</td>
</tr>
<tr>
<td>Lymphovascular invasion</td>
<td>22 (34.9)</td>
</tr>
<tr>
<td>Extrathyroidal extension</td>
<td></td>
</tr>
<tr>
<td>Microscopic</td>
<td>30 (47.6)</td>
</tr>
<tr>
<td>Gross</td>
<td>8 (12.7)</td>
</tr>
<tr>
<td>Cervical LN metastasis</td>
<td></td>
</tr>
<tr>
<td>N1a</td>
<td>29 (46.0)</td>
</tr>
<tr>
<td>N1b</td>
<td>8 (12.7)</td>
</tr>
<tr>
<td>Distant metastasis</td>
<td>0</td>
</tr>
<tr>
<td>Total thyroidectomy</td>
<td>59 (93.7)</td>
</tr>
<tr>
<td>RAI</td>
<td>53 (84.1)</td>
</tr>
<tr>
<td>RAI dose, mCi</td>
<td>104.4 ± 74.8</td>
</tr>
</tbody>
</table>

Values are expressed as mean ± standard deviation or number (%).

### Table 2. Ultrasonographic Features

<table>
<thead>
<tr>
<th>Variable</th>
<th>Number (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATA classification</td>
<td></td>
</tr>
<tr>
<td>High suspicion</td>
<td>45 (75.0)</td>
</tr>
<tr>
<td>Intermediate suspicion</td>
<td>15 (25.0)</td>
</tr>
<tr>
<td>Low suspicion</td>
<td>0</td>
</tr>
<tr>
<td>Very low suspicion</td>
<td>0</td>
</tr>
<tr>
<td>Benign</td>
<td>0</td>
</tr>
<tr>
<td>Echogenicity</td>
<td></td>
</tr>
<tr>
<td>Hypoechoic</td>
<td>50 (83.3)</td>
</tr>
<tr>
<td>Isoechoic</td>
<td>10 (16.7)</td>
</tr>
<tr>
<td>Calcification</td>
<td></td>
</tr>
<tr>
<td>Microcalcification</td>
<td>26 (43.3)</td>
</tr>
<tr>
<td>Macrocalcification</td>
<td>4 (6.7)</td>
</tr>
<tr>
<td>Rim calcification</td>
<td>0</td>
</tr>
<tr>
<td>Micro- and macrocalcification</td>
<td>2 (3.3)</td>
</tr>
<tr>
<td>Margin, irregular or microlobulated</td>
<td>46 (76.7)</td>
</tr>
<tr>
<td>Shape, taller-than-wide</td>
<td>22 (36.7)</td>
</tr>
</tbody>
</table>

ATA, American Thyroid Association.
ditionally, we evaluated RFS according to the clinical behaviors of the variants; the 5-year RFS rate for variants with favorable, less favorable, and aggressive outcomes were 100.0%, 71.4%, and 95.9%, respectively (Fig. 2B). Interestingly, patients with less favorable outcomes had worse RFS than those with aggressive outcomes (HR, 7.7; 95% CI, 1.1 to 54.8; P = 0.041). Additionally, we performed a subgroup analysis to identify the prognostic factors in patients with rare variants. Patients with DSV had significantly poorer RFS than those with other variants (HR, 17.1; 95% CI, 2.4 to 121.7; P = 0.005) (Fig. 3). There was no significant difference in RFS with respect to other factors, such as age, sex, primary tumor size, lymphovascular invasion, ETE, RAI therapy, and US features (data not shown).

**Characteristics of PTC patients with DSV**

Table 3 summarizes the data on clinical and pathological characteristics of the four patients with DSV. All patients were between 20 and 30 years of age, and three (75%) were females. Three of the patients had primary tumors larger than 1 cm. All patients with DSV underwent total thyroidectomy and developed neck LN metastases with extensive LN involvement (range, 2 to 29). A 33-year-old male underwent total thyroidectomy and neck dissection, with pathology reporting 29 of 61 LN positive for DSV subtype of PTC. Preoperative US and computed tomography images showed no evidence of suspicious LNs in both sides of the neck. The 6-month post-RAI scan showed activity in the right level III LN. A right lateral neck dissection was performed, and pathology reported one of 7 LN to be positive for PTC. Three patients (75%) had pathological features of Hashimoto’s thyroiditis. The US findings indicated that the DSV tumors could be classified into high suspicion (50%) or intermediate suspicion (50%) categories; however, these features are not helpful in predicting recurrence at the time of diagnosis. Two patients (50%) developed disease recurrence in the lateral neck at 6 and 51 months after thyroidectomy, respectively.
**DISCUSSION**

Our retrospective investigation is the first large, multicenter study in Korea that evaluated the clinicopathological characteristics and RFS of the rare variants of PTC. Out of the 5,496 patients included in the study, only 63 patients exhibited rare variants of PTC, accounting for 1.1% of all PTC cases. TCV was the most frequent variant with an incidence of 0.9%. We determined that some PTC patients with rare variants exhibited aggressive features; 12.7% each demonstrated gross ETE and lateral neck LN metastasis. Based on the ATA classification and US features, we classified all tumors into high or intermediate suspicion categories, with most belonging to the former category. During the follow-up period, locoregional recurrence occurred in 6.3% of the patients. The 5-year RFS rates for variants with favorable, less favorable, and aggressive outcomes were 100%, 71.4%, and 95.9%, respectively. Additionally, DSV emerged as an independent risk factor associated with a shorter RFS.

The pathological definitions of these variants of PTC have changed over time, thus varying the incidences of these tumors accordingly [9,27]. We defined TCV as a tumor with more than 50% tall cells that are ≥3 times as tall as wide. This rigorous definition may have contributed to a lower incidence of TCV compared to that previously reported [5,7,10,11]. A recent World Health Organization classification defined that tall cells should account for more than 30% of all tumor cells for the diagnosis of TCV. However, evidence shows that a tumor with more than 50% tall cells significantly and independently affects prognosis, whereas that with 30% to 49% tall cells does not [28]. Standardizing diagnostic criteria and accurately diagnosing rare variants of PTC are important to determine the patients who require extensive therapies, including a completion thyroidectomy followed by RAI ablation and aggressive surveillance.

This retrospective study was designed to examine the incidence and biological behaviors of rare variants of PTC, based on the pathology reports of patients with PTC. All pathology slides were reviewed by institutional pathologists to better represent clinical practice, and the incidence of rare variants varied from 0% to 5.6% for all PTCs in each institution. The uncommon variants may be easily overlooked by inexperienced pathologists, and these variants of PTC might be underdiagnosed by general pathologists, who tend to classify rare variants as classical PTC. This might be an explanation for the wide range of incidence of rare variants in this study and previous studies [29-31]. The incidence of TCV has been reported to range from 1.3% to 13% of all PTCs [29]. When carefully scrutinized for the diagnosis of TCV by endocrine pathologists, the proportion of TCV has been observed to increase [29]. The proportions of TCV diagnosed at a single institution in Korea were 4.9% and 6.8% of all PTCs in 2013 and in 2020, respectively [30,31], when all pathology slides were reviewed by an expert.

In the present study, most of the rare variants of PTC exhibited typical malignant features on US: solid hypoechoic nodules with irregular/microlobulated margins and microcalcifications. Little information exists on the imaging features of these rare variants of PTC due to their rarity [32,33]. In a retrospective study of eight patients with 10 TCVs, TCV appeared as markedly hypoechoic nodules with microlobulated margins, microcalcifications, and ETE [34]. SVs also were diagnosed as high or intermediate suspicion nodules on US [32,35]. Yun et al. [36], in their study of 17 DSV cases, described the characteristic US features that included diffuse and scattered microcalcifications with heterogeneous hypoechogenicity. On the contrary, CMVs that have indolent tumors did not exhibit malignant features on US [37]. Therefore, US features can be considered as indicators of tumor aggressiveness. Further research may help determine the incidence and biological behaviors of rare variants of PTC.

### Table 3. Clinical Characteristics of the Four Papillary Thyroid Carcinoma Patients with Diffuse Sclerosing Variant

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age, yr</th>
<th>Sex</th>
<th>Primary tumor size, cm</th>
<th>TNM stage</th>
<th>Metastatic LNs</th>
<th>Background</th>
<th>US category</th>
<th>Recur</th>
<th>Recurred area</th>
<th>RFS, mo</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>33</td>
<td>M</td>
<td>3.5</td>
<td>T3N1aM0</td>
<td>29</td>
<td>None</td>
<td>Intermediate</td>
<td>Yes</td>
<td>Lat. neck LNs</td>
<td>6</td>
</tr>
<tr>
<td>2</td>
<td>21</td>
<td>F</td>
<td>1.1</td>
<td>T1N1aM0</td>
<td>6</td>
<td>HT</td>
<td>Intermediate</td>
<td>Yes</td>
<td>Lat. neck LNs</td>
<td>51</td>
</tr>
<tr>
<td>3</td>
<td>32</td>
<td>F</td>
<td>2.0</td>
<td>T3N1bM0</td>
<td>22</td>
<td>HT</td>
<td>High</td>
<td>No</td>
<td>-</td>
<td>88</td>
</tr>
<tr>
<td>4</td>
<td>26</td>
<td>F</td>
<td>0.9</td>
<td>T1N1aM0</td>
<td>2</td>
<td>HT</td>
<td>High</td>
<td>No</td>
<td>-</td>
<td>67</td>
</tr>
</tbody>
</table>

TNM, tumor-node-metastasis; LN, lymph node; US, ultrasonography; RFS, recurrence-free survival; HT, Hashimoto’s thyroiditis; Lat., lateral. *According to the 7th edition of the TNM staging system; †According to the American Thyroid Association classification systems.
if US features can effectively predict prognosis in these variants of PTC. In this study, we found it difficult to assign specific characteristics for each variant and determine their prognostic implications due to a high proportion of patients with TCV and a wide overlap of US features among the variants.

Using ATA classification, the 5-year RFS rates for variants with favorable, less favorable, and aggressive outcomes were 100%, 71.4%, and 95.9%, respectively. In our study, the variants with less favorable outcomes had a significantly shorter RFS than those with aggressive outcomes. One possible explanation for our findings is the proportion of variants included in our analysis. None of our patients exhibited CCV and HV, which have been reported to be associated with recurrence, metastasis, and disease-specific death [10,38]. Another possibility is that we evaluated only for RFS, and not for disease-specific survival. Although DSV has more aggressive pathological features and are treated more aggressively than classical PTC, most studies revealed that it did not depict any adverse effects or a higher mortality rate [13,14]. However, a systematic review of DSV demonstrated that it was associated with worse overall survival [39]. Evaluating the long-term outcomes with a larger cohort may help explain the prognostic significance of each pathological variant.

Consistent with previous studies, our data indicated that DSV occurs at a younger age with a high incidence of cervical LN metastasis [22,24]. Additionally, a higher prevalence of underlying Hashimoto’s thyroiditis and a higher female-to-male ratio are unique clinical features of DSV [13]. Abundant lymphocytic infiltration is a characteristic of DSV, and the molecular profile of DSV may be a possible explanation for its pathological difference from classical PTC [40]. RET/PTC rearrangements are common in DSV, whereas BRAF mutations are observed in DSV at a lower frequency compared to classical PTC [41,42]. Our analysis of the Cox proportional hazards model revealed that DSV is a significant prognostic factor for RFS among patients with rare variants of PTC. It is noteworthy that all recurrences were locoregional and that the preoperative US features were not helpful in predicting recurrence. This suggests that close monitoring of the operation bed and lateral neck LNs is of importance during the follow-up after initial therapy for patients with DSV.

The present study has several limitations. First, this study is retrospective by design and involves a relatively small number of PTC patients with rare variants due to their inherent rareness and short period of data collection. This retrospective multicenter study was conducted after reviewing all pathology slides reported as PTC in each institution. We reviewed patients diagnosed with PTC over a year to allow more institutions to participate, and actually reviewed all pathology slides for 5,496 PTC cases. We also intend to evaluate the prognosis of patients with a follow-up period of 5 years or longer in patients diagnosed with a rare variant of PTC in 2012. Second, we failed to conduct centralized pathological examinations in this multicentered study, and there may have been discrepancies among the pathologists’ interpretation of the diagnosis criteria. Third, the median follow-up duration of 7 years was relatively short to evaluate the recurrence. Additionally, no disease-specific death occurred during this period. Further studies using cohorts with longer data collection periods will yield more definitive results. However, this is the first multicenter cohort study to evaluate the clinicopathological characteristics and biological behaviors of rare variants of PTC in Korea.

In conclusion, our multicentered Korean cohort revealed that rare variants of PTC accounted for 1.1% of all PTCs with TCV being the most frequent variant. Locoregional recurrences occurred in four patients, and DSV was the only variant that emerged as a significant prognostic factor for RFS. These findings suggest that pathological variant should be taken into consideration while determining the follow-up and treatment strategies in patients with PTC. Further studies conducted on a larger scale are needed to verify the incidence, clinicopathological characteristics, and biologic behaviors.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGMENTS

This work was supported by the Korean Thyroid Association Clinical Research Award 2019.

AUTHOR CONTRIBUTIONS

ORCID

Mijin Kim https://orcid.org/0000-0002-1538-8859
Sun Wook Cho https://orcid.org/0000-0002-7394-3830
Chan Kwon Jung https://orcid.org/0000-0001-6843-3708
Bo Hyun Kim https://orcid.org/0000-0001-9632-9457

REFERENCES

2. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006;16:1229-42.
20. Ito M, Bogdanova T, Zurnadzy L, Saenko V, Rogounovitch T, Mitsutake N, et al. Morphological difference in adult thyroid papillary carcinoma between Japan and Ukraine. En-
Variants of Papillary Thyroid Carcinomas


